Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate

Mebias Discovery Receives Grant from NIDA to Advance its Signaling-Pathway Selective MU-Opioid Receptor Drug Candidate
Preclinical Studies of lead molecules have shown absence of respiratory depression, rewarding behavior, sedation, and constipation associated with traditional opioids    

See more here

Comments are closed.